FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia July 13, 2021 A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up December 22, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... How we can reduce cancer risk in inflammatory bowel disease patients...
